Solid Tumor Refractory to Standard Therapy
Conditions
Brief summary
This is a single-center, double-blind, single-dose escalation study in healthy volunteers.
Detailed description
This is a single-center, double-blind, single-dose escalation study in healthy volunteers consisting of a 14-day Screening Period, 1-day Predose period, a 2-day Dosing and Evaluation Period, and a 5-day Follow-up Period, with a single Follow-up call scheduled on Day 7 ± 1. Subjects will be confined to the study site for up to 3 days (admitted on Day -1 and discharged on Day 2 or 3, depending on cohort) and will be monitored for adverse events (AEs) and dose limiting toxicities (DLT) during the Dosing, Evaluation and Follow-up Periods. Subjects will also be monitored for concomitant medications and use of rescue medications throughout the study. Subjects will be allocated 1:4 to receive an infusion of saline control (0.9% saline for injection) or Shenqi Fuzheng Injection(SQ-001) continuously for about 1-4 hours. SQ 001 will be administered by intravenous route at a rate of 3 mL/min to one of four final dosages: Cohort 1 (125 mL/day/person), Cohort 2 (250 mL/day/person), Cohort 3 (500 mL/day/person), and Cohort 4 (625 mL/day/person). Each cohort will be enrolled sequentially. Per cohort, three subjects will be dosed initially on Day 1 and observed for 24 hours. If there are no observed AEs that meet the criteria under Stopping Rules, the remaining 7 subjects/cohort will be dosed. Dose escalation to the next higher dose will be based on the observation of results in safety and degree of AEs from the previous cohort and discussion between the Investigator and Sponsor. A maximum 17 PK samples will be collected over the course of the study in each cohort. The PK sampling time points will be grouped as (a) pre-infusion; (b) intra-infusion; (c) completion of infusion; and (d) post-infusion. See Table 10 for plasma PK sampling times. The last PK sample will be collected 24 hours after the end of infusion.
Interventions
DRUGSQ001 125mL/day
SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
DRUGSQ001 250mL/day
SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
DRUGSQ001 500mL/day
SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
DRUGSQ001 625mL/day
SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
DRUGSaline 0.9%
Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
Sponsors
Palm Beach CRO
Keystone Bioanalytical, Inc.
Livzon Pharmaceutical Group Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subjects must be medically documented as healthy at the time of screening as determined by their medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory tests, unless the Investigator considers an abnormality to be clinically irrelevant. 2. Subjects must be within 18 to 65 years old and not currently using tobacco products. 3. Subjects must have a BMI within 18 to 32 kg/m2. 4. Females 1. Surgically sterilized (e.g., hysterectomy or bilateral oophorectomy) for at least 6 months prior to screening or postmenopausal (postmenopausal women must have no menstrual bleeding for at least 1 year prior to screening and menopause will be confirmed by a plasma FSH level of \>30 IU/L) or 2. Women of child-bearing potential must be non-lactating and agree to use a highly effective acceptable form of birth control such as surgical sterilization (e.g., tubal ligation), or total abstinence from sexual intercourse with the opposite sex, or established hormonal birth control (e.g. oral, implant or injection) plus a barrier method, or a double barrier method (e.g. intrauterine device plus condom or spermicidal gel plus condom or diaphragm plus condom) from 14 days prior to dosing until 30 days after dosing. 3. Women with a negative serum pregnancy test (βhCG assay) at screening and at Day -1 (urine) 4. For non-sexually active females, abstinence may be regarded as an adequate method of birth control, but if the subject becomes sexually active during the study, she must use adequate birth control as defined above for the remainder of the study. 5. Males Must be willing to use highly effective forms of acceptable birth control (e.g., vasectomy, total abstinence from sexual intercourse with the opposite sex, sexual intercourse with a woman who is not of childbearing potential) from Day 1 dosing to Day 90 after dose. 6. Subjects must be able to comply with the study and follow-up procedures. 7. Subjects must provide a signed informed consent to participate in the study. 8. Subjects must not have participated in any clinical trial within 30 days.
Exclusion criteria
1. Any condition preventing reliable phlebotomy or infusion from the cubital fossa. 2. Documented history of clinically significant unstable medical illness. 3. History of clinically significant drug, food, or environmental allergy. 4. Subjects with any uncontrolled medical condition deemed clinically significant by an Investigator. 5. Clinically significant safety laboratory, 12-lead ECG, or vital sign abnormalities during screening or Day -1 that would place the subject at undue risk based on the Investigator's opinion, including but not limited to: 1. History of cardiac conditions that might give a higher risk of an increase in heart rate 2. Fridericia's corrected QT interval (QTcF) interval of \>450 msec on 12-lead ECG 3. Alanine aminotransferase (ALT) \>1.2 × upper limit of normal (ULN), aspartate aminotransferase (AST) \>1.2 × ULN 4. Blood urea nitrogen (BUN) or serum creatinine \>1.2 × ULN 6. Subjects who are positive for HIV, HBV, and/or HCV. 7. Subjects who have used prescription drugs, over-the-counter drugs, or herbal remedies within 14 days before Day 1 of study medication dosing. 8. Women who are pregnant or breast feeding. 9. Subjects who participated in a clinical trial within 30 days prior to Day 1 study medication dosing. 10. Subjects with any condition that, in the judgment of the Principal Investigator, would place a subject at undue risk, or potentially compromise the results or interpretation of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Volume of distribution at steady state (Vdss)(L/kg) | On 1 and 2 days (dosing day and the following evaluation day) | To compare the Vdss of 3 major representative (sentinel) compounds astragaloside IV, calycosin 7-O-β-glucopyranoside, and lobetyolinin different experimental arms |
| Area under the concentration-time curve (AUC)(ng·h/mL) | On 1 and 2 days (dosing day and the following evaluation day) | To compare the AUC of 3 major representative (sentinel) compounds astragaloside IV, calycosin 7-O-β-glucopyranoside, and lobetyolin in different experimental arms |
| Elimination half-life (T1/2)(h) | On 1 and 2 days (dosing day and the following evaluation day) | To compare the Cmax of 3 major representative (sentinel) compounds astragaloside IV, calycosin 7-O-β-glucopyranoside, and lobetyolin in different experimental arms |
| Apparent clearance (CL)(mL/min/kg) | On 1 and 2 days (dosing day and the following evaluation day) | To compare the CL of 3 major representative (sentinel) compounds astragaloside IV, calycosin 7-O-β-glucopyranoside, and lobetyolinin different experimental arms |
| The maximum observed concentrations (Cmax)(ng/mL) | On 1 and 2 days (dosing day and the following evaluation day) | To compare the Cmax of 3 major representative (sentinel) compounds astragaloside IV, calycosin 7-O-β-glucopyranoside, and lobetyolin in different experimental arms |
| Time to reach Cmax (Tmax)(h) | On 1 and 2 days (dosing day and the following evaluation day) | To compare the Tmax of 3 major representative (sentinel) compounds astragaloside IV, calycosin 7-O-β-glucopyranoside, and lobetyolin in different experimental arms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of treatment-related adverse events | From predose to up to 5 days following the dosing and evaluation period | Frequency of treatment-related adverse events as assessed by CTCAE v4.03 |
| Grade of treatment-related adverse events | From predose to up to 5 days following the dosing and evaluation period | Grade of treatment-related adverse events as assessed by CTCAE v4.03 |
| Incidence of treatment-related adverse events | From predose to up 5 days following the dosing and evaluation period | Incidence of treatment-related adverse events as assessed by CTCAE v4.03 |
Countries
United States
Outcome results
None listed